Fusion proteins for the treatment of disease
Patent Information
- Application Number
- JP2023526282
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-10
- Filing Date
- 2021-10-29
- Publication Date
- 2024-11-07
- Estimated Expiration
- Not applicable · inactive patent
Abstract
Claims
1. An interleukin-2 (IL2) fusion protein for use in treating a disease or disorder in a subject in need thereof, wherein a dose of the IL2 fusion protein is administered to the subject, and the fusion protein comprises: a first polypeptide comprising an IL2 polypeptide; and A second polypeptide comprising the extracellular domain of an interleukin-2 receptor alpha (IL2Rα) polypeptide. Including; (i) the extracellular domain of the IL2Rα polypeptide has at least one less glycosylation site compared to the extracellular domain of native IL2Rα (SEQ ID NO:1); and / or (ii) the IL2 polypeptide has at least one less glycosylation site compared to native IL2 (SEQ ID NO:2); and The dosage is from about 0.3 mg to about 9 mg. Fusion proteins.
2. 2. The fusion protein for use according to claim 1, wherein the fusion protein is administered to a subject via intravenous, subcutaneous, topical, epidermal, mucosal, intranasal, oral, intravaginal, rectal, sublingual, intraperitoneal, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, transtracheal, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural or intrasternal routes.
3. The fusion protein for use according to claim 2, wherein the fusion protein is administered to a subject via the intravenous route.
4. The fusion protein for use according to claim 2, wherein the fusion protein is administered to a subject via the subcutaneous route.
5. The fusion protein for use according to any one of claims 1 to 4, wherein the dose is about 1 mg, about 3 mg, about 6 mg, or about 8 mg.
6. 6. The fusion protein for use according to any one of claims 1 to 5, wherein two or more of the doses are administered with a dosing interval between the two doses, the dosing interval being at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least about 1 month, at least about 5 weeks, at least about 6 weeks, at least about 7 weeks, at least about 8 weeks, at least about 2 months, at least about 9 weeks, at least about 10 weeks, at least about 11 weeks, at least about 12 weeks, or at least about 3 months.
7. The fusion protein for use according to claim 6, wherein the dosing interval is about 3 weeks.
8. The fusion protein for use according to claim 6 or 7, wherein the dosing intervals are the same or different throughout the dose.
9. 9. The fusion protein for use according to any one of claims 6 to 8, wherein at least one of the two or more doses is administered intravenously and at least one of the two or more doses is administered subcutaneously.
10. 10. The fusion protein for use according to any one of claims 1 to 9, wherein the disease or disorder comprises an infectious disease or an immune-mediated disease.
11. Immune-mediated diseases include type 1 diabetes; multiple sclerosis; rheumatoid arthritis; celiac disease; systemic lupus erythematosus; lupus nephritis; cutaneous lupus; juvenile idiopathic arthritis; Crohn's disease; ulcerative colitis; systemic sclerosis; graft-versus-host disease (GvHD); psoriasis; alopecia areata; HCV-induced vasculitis; Sjogren's syndrome; pemphigus; ankylosing spondylitis; Behcet's disease; Wegener's granulomatosis; Takayasu's disease ; Autoimmune hepatitis; sclerosing cholangitis; Gujeró-Sjögren's disease; 11. The fusion protein for use according to claim 10, selected from the group consisting of inflammatory bowel disease; immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome; and macrophage activation syndrome.
12. The fusion protein for use according to claim 10 or 11, wherein the subject is administered a corticosteroid.
13. The fusion protein for use as described in claim 12, wherein: (a) the corticosteroid is administered to the subject via topical, oral, intravenous, or intramuscular routes; (b) the corticosteroid is administered before, simultaneously with, or after each dose of the fusion protein; or (c) both (a) and (b).
14. A fusion protein for use as described in any one of claims 1 to 13, wherein: (a) the extracellular domain of the IL2Rα polypeptide has at least one less glycosylation site, at least two less glycosylation sites, at least three less glycosylation sites, at least four less glycosylation sites, at least five less glycosylation sites, at least six less glycosylation sites, at least seven less glycosylation sites, at least eight less glycosylation sites, or at least nine less glycosylation sites compared to the extracellular domain of native IL2Rα (SEQ ID NO: 1); (b) the IL2 polypeptide has at least one less glycosylation site compared to native IL2 (SEQ ID NO: 2); or (c) both (a) and (b).
15. A fusion protein for use according to any one of claims 1 to 14, wherein: (a) the first polypeptide comprises an amino acid sequence that is at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO:2; (b) the second polypeptide comprises an amino acid sequence that is at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO:3; or (c) both (a) and (b).
